Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron has started 2025 with an increase ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's bottom line came in at ...

In short, there are no easy wins within Regeneron's pipeline in my view, although there are some intriguing data readouts and regulator approval shots in play in 2025, as per the below slide ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. While we feel good about high insider ownership of Regeneron Pharmaceuticals ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.